How many investments has Prospect Venture Partners made?

Prospect Venture Partners has 29 tracked investments, 11 of which have exited.

What stage does Prospect Venture Partners invest at?

Prospect Venture Partners invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What is Prospect Venture Partners's typical check size?

Prospect Venture Partners typically writes checks of $3M – $5M.

What sectors does Prospect Venture Partners focus on?

Prospect Venture Partners focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.

Where is Prospect Venture Partners located?

Prospect Venture Partners is headquartered in Menlo Park, US.

Does Prospect Venture Partners lead rounds?

Yes, Prospect Venture Partners leads investment rounds.

Who does Prospect Venture Partners co-invest with?

Prospect Venture Partners most often shares deals with New Enterprise Associates (NEA), Aisling Capital, Foresite Capital, among 32 tracked co-investors.

Prospect Venture Partners

Venture capital

Menlo Park · Seed–Late Stage · 4 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Prospect Venture Partners

17 people in our graph share verified history with the Prospect Venture Partners team — schools, employers, funds. One of them is your warm intro.

Avery Cannonunlockedknows Alexander E. Barkas · together at Prospect Venture Partners

×2knows the team · via SentreHeart

×8knows the team · via Prospect Venture Partners

knows the team · via Ngm Biopharmaceuticals

✨ Fox Verdict

Investment thesis

Prospect Venture Partners focuses on biomedical innovation, supporting entrepreneurs pursuing growth opportunities across health care, biotechnology, and medical devices. The firm partners closely with management teams to help build strong companies, drawing on a track record established since its founding in 1997.

Invests inBiotech Deep Tech Digital Health Healthtech Medical Devices Menlo Park Palo Alto United States

Source: firm website, verified Aug 3, 2026.

Stage

Seed–Late Stage

Check

$3M – $5M

Menlo Park, California, US

Leads rounds

Leads

Instruments

Equity

Founded

1997

AUM

$100M

Tracked investments

IPOs

Acquisitions

Team · 4 people

from the firm's website & public directories

Alexander E. Barkas· Co-Founder

Alex Barkas was a co-founder of Prospect Ventures, which he established to focus on developing and commercializing biomedical technologies. He previously served as a Partner at Kleiner Perkins Caufield & Byers, where he worked on biotechnology and medical device investing and co-founded and led several biotechnology companies, and earlier founded the healthcare consulting firm BioBridge Associates. He held a PhD in Biology from New York University and a BA in Biology from Brandeis University, with prior research experience at Memorial Sloan Kettering Cancer Center, the Toronto Hospital for Sick Children, the Whitehead Institute at MIT, and Duke University.

David Schnell· Managing Director· Menlo Park, California

David Schnell is a Managing Director who co-founded Prospect Ventures in 1997, a firm focused on biomedical companies. He was previously a Partner at Kleiner Perkins Caufield & Byers, where he invested in early-stage biotechnology companies, and co-founded and served as CEO of Healtheon Corporation, which later merged with WebMD. Earlier he spent seven years at Sandoz Pharmaceuticals (now Novartis) in executive roles; he holds an MD from Harvard Medical School and an MA and BS from Stanford.

d•••@prospectventures.comreveal

Russell Hirsch· Managing Director

Russell Hirsch is a co-founder and Managing Director of Prospect Venture Partners, focusing on life science investments in biotechnology and medical device companies. He previously served as a General Partner at the Mayfield Fund, where he helped build its biotechnology and medical device practice. Before his venture career, he worked as a research scientist, earning his MD and PhD from UCSF and conducting research on hepatitis B viral replication.

r•••@prospectventures.comreveal

Daniel Mendoza· Executive Officer

Founder mafia

2 people who came through Prospect Venture Partners went on to found or lead other companies.

Scott Wolf, MDPartnerFounded Cardiac Dimensions +3 Stella SarrafScientific AdvisorFounded Spinogenix +1

What they invest in

from 13 of 29 portfolio companies

Healthtech ×10Biotech ×8Medical Devices ×5Digital Health ×2Hardware ×2New Materials ×2Advanced Manufacturing ×1Consumer ×1

HQs:United States×10Switzerland×1United Kingdom×1

Investments · 29 tracked

founders shown can be your intro path

By year:2016 · 1 2015 · 23 dated

Insmedinsmed.com in 𝕏NASDAQ: INSM

Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.

BiotechDigital HealthHealthtechMedical Devices

Will Lewis(Chair and Chief Executive Officer)inGeoffrey AllaninSara Bonstein(Chief Financial Officer)inRoger Adsett(Chief Operating Officer)Martina Flammer(Chief Medical Officer)in S. Nicole Schaeffer(Chief People Strategy Officer)in

Co-investorsBessemer Venture Partners F-Prime Capital Foresite Capital OrbiMed NVIDIA

Curileumcurileum.com in✓ verified

Curileum develops regenerative medicine therapies targeting intestinal stem cells to prevent colorectal cancer.

BiotechHealthtechMedical DevicesLondon, GB

Dr Jeff Moore(Founder & CEO)

Co-investorsAtlas Venture Biotechnology Value Fund Canaan Partners Oxford Technology Management

Amicus Therapeuticsamicusrx.com in

Amicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions.

BiotechHealthtechCranbury, US

Daphne Quimi(Executive Officer)John Crowley(Executive Officer, Director)William D. Baird, III(Executive Officer)

BoardCraig A. Wheeler(Director)Ted W. Love(Director)inMargaret G. McGlynn(Director)

Co-investorsAvoro Capital Advisors Canaan Partners Frazier Life Sciences New Enterprise Associates (NEA)

Gloucester Pharmaceuticalsbms.com in 𝕏Acquired

Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.

BiotechHealthtechMedical DevicesNew York, US

Co-investorsKleiner Perkins New Enterprise Associates (NEA)Nextech Invest Rho Capital Partners Rho Ventures RiverVest Venture Partners +2 more

Jazz Pharmaceuticaljazzpharma.com in 𝕏

Jazz Pharmaceuticals is a biopharmaceutical company developing treatments for rare diseases and cancers, with a focus on oncology and biomarker-driven therapies such as those targeting HER2-expressing cancers.

BiotechHealthtech

Co-investorsLongitude Capital Rex Health Ventures Solas BioVentures

Kythera Biopharmaceuticalsallergan.comAcquired

Aesthetic-medicine biopharma behind KYBELLA (deoxycholic acid) injection, acquired by Allergan in 2015 for ~$2.1 billion.

Co-investorsAisling Capital ARCH Venture Partners Schooner Capital ALTITUDE LIFE SCIENCE VENTURES Foley Ventures Invus

Nanosysnanosys.com inAcquired

Nanosys develops Quantum Dot technology and materials, providing samples, R&D collaboration, and scaled production for partners building display and other advanced-material products.

Advanced ManufacturingDeep TechHardwareNew MaterialsSemiconductorsMilpitas, US

Jason Hartlove(Executive Officer, Director)inJian Chen(Executive Officer)in Russell Kempt(Executive Officer)inNoland Granberry(Executive Officer)in

Board Keith Crandell(Director)Steven Goldby(Director)

Co-investorsStructural Capital TEL Venture Capital, Inc.Venrock ARCH Venture Partners Centerbridge Partners, L.P.Fortress Investment Group +1 more

NinePoint Medical in

HealthtechBedford, US

Christopher von Jako(Executive Officer, Director)Judith M. Huber(Executive Officer)Charles Carignan(Executive Officer, Director)Eric Swanson(Director)

BoardRussell Hirsch(Director)Mark Levin(Director)in

Co-investorsThird Rock Ventures

Opus Medicalopusmedical.com in

Opus Medical provides personalized case management services for injured workers, matching clinical oversight to the severity of each injury.

Digital HealthEnterprise SoftwareHealthtechInsurTechMedical DevicesNashville, US

Melissa D. Tonn(Chief Medical Officer)in

Co-investorsCouncil

Senomyxfirmenich.com in 𝕏Acquired

Firmenich is a co-creation and innovation partner specializing in nutrition, health, and beauty ingredients and solutions.

ConsumerHealthtechNew MaterialsGeneva, CH

Gilbert Ghostinein

Co-investorsBay City Capital Rho Ventures

SentreHeartsentreheart.com in 𝕏Sep 2016

SentreHeart appears to now redirect to AtriCure, Inc., a medical device company.

BiotechHardwareHealthtechMedical DevicesRedwood City, US

Russell Seiber(Executive Officer, Director)in Pam Simons(Executive Officer)inGreg Fung(Executive Officer)Robert Strasser(Executive Officer)in

Board Phil Young(Director)inVictor Tong(Director)

PartnerRussell Hirsch· led

Co-investorsUS Venture Partners

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Amira PharmaceuticalsAveo PharmaceuticalsCabochonComplete GenomicsHansen MedicalHealth Systems TechnologiesIdun PharmaceuticalsInfinity PharmaceuticalsMillennium PharmaceuticalsNgm BiopharmaceuticalsNovaceptPortola PharmaceuticalsRinat NeuroscienceSurgRxTercicaTherOxTopica PharmaceuticalsTrubion

Exits · 11

1 IPOs · 10 acquisitions · showing 7

InsmedNASDAQ: INSMAmira Pharmaceuticalsacq. by Bristol Myers SquibbMillennium Pharmaceuticalsacq. by Takeda PharmaceuticalNgm Biopharmaceuticalsacq. by The Column GroupPortola Pharmaceuticalsacq. by AlexionTopica Pharmaceuticalsacq. by MedicisTrubionacq. by Emergent Biosolutions

Portfolio news

latest coverage across their companies

BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth - Daily Political

Amicus Therapeutics · dailypolitical.com · Aug 15, 2026

Venture funding drops in Seattle area as AI boom reshapes startup world – GeekWire

Insmed · geekwire.com · Jul 13, 2026

Frequently asked questions

How many investments has Prospect Venture Partners made?: Prospect Venture Partners has 29 tracked investments, 11 of which have exited.
What stage does Prospect Venture Partners invest at?: Prospect Venture Partners invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is Prospect Venture Partners's typical check size?: Prospect Venture Partners typically writes checks of $3M – $5M.
What sectors does Prospect Venture Partners focus on?: Prospect Venture Partners focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
Where is Prospect Venture Partners located?: Prospect Venture Partners is headquartered in Menlo Park, US.
Does Prospect Venture Partners lead rounds?: Yes, Prospect Venture Partners leads investment rounds.
Who does Prospect Venture Partners co-invest with?: Prospect Venture Partners most often shares deals with New Enterprise Associates (NEA), Aisling Capital, Foresite Capital, among 32 tracked co-investors.

Similar investors

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Capricorn Venture Partners

Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.

$270K – $10.8M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Eight Roads Ventures

Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.

$5M – $30M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

$250K – $50M